目的:探究二甲双胍联合达格列净对糖尿病肾病患者的影响。方法:选取 2022 年 1 月—2024 年 1 月广州市番禺区第七人民医院收治的 120 例糖尿病肾病患者作为研究对象。根据随机数表法将其分为观察组和对照组，各 60 例。对照组给予二甲双胍治疗，观察组在对照组基础上给予达格列净治疗。比较两组治疗前后血糖指标、肾功能指标、血压指标及不良心血管事件。结果:治疗后，两组糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后 2 h血糖(2 h PG)均降低，观察组HbA1c、FPG、2 h PG均低于对照组，差异有统计学意义(P<0。05)。观察组不良心血管事件发生率低于对照组，差异有统计学意义(P<0。05)。治疗后，两组血尿素氮(BUN)、血肌酐(Scr)、尿白蛋白/肌酐比值(UACR)、24 h尿微量白蛋白均低于治疗前，观察组BUN、Scr、UACR、24 h尿微量白蛋白均低于对照组，差异有统计学意义(P<0。05)。治疗后，两组收缩压、舒张压均低于治疗前，观察组收缩压、舒张压均低于对照组，差异有统计学意义(P<0。05)。结论:二甲双胍联合达格列净可起到保护人体肾脏和心血管的作用，且安全性较高。
Effect of Metformin Combined with Dapagliflozin on Diabetic Nephropathy Patients
Objective:To investigate the effect of Metformin combined with Dapagliflozin on diabetic nephropathy patients.Method:A total of 120 diabetic nephropathy patients admitted to the Seventh People's Hospital of Panyu District,Guangzhou City from January 2022 to January 2024 were selected as the study objects.They were divided into observation group and control group according to random number table method,with 60 cases in each group.The control group was treated with Metformin,and the observation group was treated with Dapagliflozin on the basis of the control group.Blood glucose indexes,renal function indexes,blood pressure indexes before and after treatment and adverse cardiovascular events were compared between the two groups.Result:After treatment,glycosylated hemoglobin(HbA1c),fasting blood glucose(FPG)and 2 h postprandial blood glucose(2 h PG)in both groups were decreased,and HbA1c,FPG and 2 h PG in observation group were lower than those in control group,the differences were statistically significant(P<0.05).The incidence of adverse cardiovascular events in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).After treatment,blood urea nitrogen(BUN),blood creatinine(Scr),urinary albumin/creatinine ratio(UACR)and 24 h urinary microalbumin in the two groups were lower than those before treatment,and BUN,Scr,UACR and 24 h urinary microalbumin in observation group were lower than control group,the differences were statistically significant(P<0.05).After treatment,the systolic blood pressure and diastolic blood pressure of the two groups were lower than those before treatment,and the systolic blood pressure and diastolic blood pressure of the observation group were lower than those of the control group,the differences were statistically significant(P<0.05).Conclusion:Metformin combined with Dapagliflozin can play a role in protecting human kidney and cardiovascular function,and the safety is high.
万方数据
维普
